Abstract Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological and neuropathological studies have implicated Ca V 1.3 subtype calcium channels in the pathogenesis of the disorder, and drugs with some selectivity for this ion channel (brainpenetrant dihydropyridine calcium channel blockers) are neuroprotective in animal models of the disease. Dihydropyridines have been safely used for decades to treat hypertension and other cardiovascular disorders. A phase II clinical trial found that isradipine was safely tolerated by patients with Parkinson's disease, and a phase III trial is currently underway to determine whether treatment with isradipine is neuroprotective and therefore able to slow the progression of Parkinson's disease. This manuscript reviews the current information about the use of dihydropyridines as therapy for Parkinson's disease and discusses the possible mechanism of action of these drugs, highlighting Ca V 1.3 calcium channels as a potential therapeutic target for neuroprotection in Parkinson's disease.
Introduction
Parkinson's disease is a progressive hypokinetic neurodegenerative neurological disorder characterised by bradykinesia, rigidity, akinesia, abnormal posture and resting tremor as well as non-motor functional deficits such as autonomic and sensorimotor dysfunction, cognitive decline, depression and sleep disturbances [1] . Increasing age is the greatest risk factor for Parkinson's diseasealthough approximately 10% of cases occur before the age of 50 years-such that, worldwide, it affects up to 1% of people aged [60 years, rising to above 2% for those aged [80 years. Parkinson's disease has a devastating effect on those afflicted with the disease and the people who care for them, and increasing life expectancy and the consequent ageing population means Parkinson's disease is becoming an increasing burden on healthcare resources [2] . A treatment that can slow the inexorable process of the disease would therefore be of great benefit to both patients and society as a whole.
Current pharmacological treatments for Parkinson's disease are symptomatic and do nothing to slow or reverse the relentless progression of the disease (Table 1) . Furthermore, the disabling motor and psychiatric side effects associated with these treatments can limit their use or necessitate a reduction in dose to sub-optimal levels that do not adequately restore motor function.
The search for a disease-modifying pharmacological treatment (surgical and gene therapy approaches are not discussed in this article) is hampered because we do not know the cause of the majority of Parkinson's disease cases. Distinguishing Parkinson's disease from other forms of parkinsonism is difficult, particularly in early stages of the disease. In the past, patients who presented with some of the cardinal symptoms of Parkinson's disease and responded well to L-DOPA were generally given a diagnosis of Parkinson's disease. Although the definition of Parkinson's disease and the diagnostic criteria have been updated over the years to incorporate new findings [3] , Parkinson's disease can only be definitively confirmed post mortem when neuropathological analysis shows a loss of pigmented neurons in the substantia nigra, locus coeruleus and dorsal motor nucleus together with neuronal Lewy and pale bodies throughout the brain. Lewy bodies are abnormal aggregates of misfolded protein (predominantly alphasynuclein, but they also contain other proteins such as ubiquitin, neurofilament proteins and tau) that form when the protein-degradation system of the cell is dysfunctional or overwhelmed or when the alpha-synuclein is mutated to a form that favours the formation of insoluble fibrils. The exact function of soluble (normal) alpha-synuclein is unknown, but it is thought to be involved in neurotransmitter release and mitochondrial function. Alpha-synuclein aggregates are also found in other diseases (synucleinopathies) such as dementia with Lewy bodies, multiple system atrophy and progressive supranuclear palsy. Alphasynuclein pathology can also be present in Alzheimer's disease. Analysis of the neuropathological phenotype allows distinction of Parkinson's disease from other disorders that often present with identical symptoms (e.g. progressive supranuclear palsy and multiple system atrophy) but have a different neuropathology (e.g. alphasynuclein inclusions in oligodendrocytes). As such, Parkinson's disease is likely diagnosed for a range of disorders with overlapping symptoms, the main one clearly being parkinsonism (bradykinesia, rigidity, akinesia, abnormal posture, resting tremor), with concomitant autonomic and sensorimotor dysfunction that often precedes motor symptoms.
The discovery that mutations (and later multiplications) of alpha-synuclein can cause monogenic forms of Parkinson's disease with Mendelian autosomal-dominant inheritance [4, 5] enabled staining of Lewy bodies and neurites with antibodies raised against alpha-synuclein [6] . This led to neuropathological Braak alpha-synuclein staging of the disease, the hypothesis of spread of alpha-synuclein pathology through the brain [7] and ultimately to the recognition of a new group of neurodegenerative diseases, the synucleinopathies.
Familial forms of the disease-21 genes or genetic loci are found to be causative of, or susceptibility factors for, Parkinson's disease [8] -are often early onset, and the presentation (e.g. prominent dystonia) and progression of symptoms differ from those of idiopathic forms of the disorder. However, in most instances, the contribution of mutations to Parkinson's disease is far from clear because of limited gene penetrance and the wide range of disease phenotypes. Overall, Parkinson's disease caused by known monogenic mutations represents approximately 30% of familial and 3-5% of sporadic cases of the disorder [9] .
A central theme for the cause of Parkinson's disease was discovered in the late 1980s before a genetic basis for Parkinson's disease was considered likely: oxidative stress leading to the death of catecholamine neurons in the midbrain [10] and, when known, the function of genes that cause or increase risk for Parkinson's disease affect protein turnover or metabolism [11] . The former could cause metabolic stress due to congestion of processes within the cell, leading to inefficient function, whereas the latter presumably directly induces oxidative stress. Oxidative , which have an inverse correlation between their expression and the risk of degeneration of a neuron in Parkinson's disease. As such, altered calcium homeostasis is now also believed to be a major source of oxidative stress and is discussed further below. Abnormal protein accumulation also stems from many different sources such as misfolded or mutated (e.g. alpha-synuclein) proteins and defects in proteasome and lysosome function or the ubiquitination pathway. Abnormal protein accumulation might be effectively treated with antibodies against the protein-this has been tried in order to reduce amyloid plaques in Alzheimer's disease-or by enhancing the action of lysosome-mediated autophagy [11] . Both types of dysfunction lead to cell death in vulnerable neurons, and it is likely that patients with Parkinson's disease have a combination of factors that cause oxidative stress and abnormal protein accumulation in the aetiology of their disease. But what makes some neurons more vulnerable than other neurons or cell types in the brain? The brain is approximately 50% neurons, with the remainder comprising glia (astrocyte, microglia, oligodendrocytes) and blood vessels, among others [12] . Neurons are post mitotic and do not regenerate (with the possible exception of some cells in the hippocampus) and must therefore last a lifetime. Hence, any homeostatic problems they have will be cumulative over the lifetime of the individual. Furthermore, the specialization of neurons, that is, neurotransmission, makes them particularly vulnerable compared with other cell types. This is particularly so for projection neurons, which link different brain regions, as opposed to short interneurons, because they have long fine axons with large dendritic and synaptic fields and are often poorly myelinated [13] . So, unless manufacture and degradation occurs locally in the synapse, cellular components have a long way to travel between the cell body and the axon terminal, which itself is an energydemanding process that would place metabolic stress upon the neuron.
As stated above, both general mechanisms (protein turnover and oxidative stress) are likely to play a role in cell death in Parkinson's disease. Cases of Parkinson's disease that result predominantly from excessive mitochondrial oxidant stress are more likely to respond to calcium channel blocker therapy, whereas others in which this mechanism of toxicity is less dominant may show less clinical benefit. However, there is no means of routinely determining the extent of alpha-synuclein pathology in living patients because alpha-synuclein imaging techniques are still experimental; similarly, direct detection of oxidative stress in the living brain is not possible. As such, it is not currently possible to stratify patients with Parkinson's disease. However, because calcium channel-blocking drugs are available and approved for use in humans and have a good safety record, using them therapeutically to modulate intracellular calcium levels pharmacologically is currently easier than trying to reduce alpha-synuclein accumulation using, for example, experimental monoclonal antibodies against the (presumably) aggregated form of the protein. Therefore, use of calcium channel-blocking drugs to treat Parkinson's disease is the subject of this review.
The Role of Ca V 1 Channels in Parkinson's Disease
Calcium plays a central role in the normal functioning of neurons and is also involved in the many cellular processes (e.g. oxidative stress, mitochondrial impairment, proteasomal dysfunction, excitotoxicity, neuroinflammation, apoptosis) that can lead to cell death in Parkinson's disease [14] [15] [16] [17] [18] [19] . Ca V 1 calcium channels are distinguished from other calcium channels by their long (L)-lasting inward currents during depolarization (they were previously called L-type calcium channels) and their high sensitivity to dihydropyridines (L-type calcium channel blockers), which have been used for many years to treat hypertension and other cardiovascular diseases. However, use of calcium by a cell comes at a cost, because high concentrations of intracellular calcium are toxic, and extrusion of calcium from the cell and sequestration of calcium into intracellular stores requires energy that is derived from mitochondrial oxidative phosphorylation. The electrochemical gradient for calcium across cellular membranes is much larger (10009) than that of monovalent ions, so any process that uses calcium in the cell is very energy demanding. So, another feature of neurons vulnerable to neurodegeneration, in addition to their morphology, is that they have high energy requirements, which requires efficient mitochondrial function and good calcium-buffering capacity to prevent damage through oxidative stress or excitotoxicity [20] . One means of calcium buffering is achieved by calcium-binding proteins; the observation that degenerating neurons in the substantia nigra were mainly in areas with low levels of the calcium-binding protein calbindin-D28k suggested a role for calcium in neuronal susceptibility [21] [22] [23] . However, in addition to the varied distribution of calcium buffering found in the brain, recent studies have further implicated Ca V 1 in the pathogenesis of Parkinson's disease.
Another shared feature of midbrain dopamine neurons and the other brainstem nuclei that degenerate in Parkinson's disease is that they are autonomously active, with prominent transmembrane calcium currents that generate regular slow broad action potentials (2-4 Hz) in the absence of synaptic input [20] . This so-called pacemaking activity maintains basal neurotransmitter levels in regions innervated by these neurons, that is, dopaminergic tone. While most neurons rely exclusively on monovalent cation channels to drive such pacemaking, studies in animals indicate that neurons vulnerable to neurodegeneration in the substantia nigra pars compacta and dorsal motor nucleus of the vagal nerve preferentially use Ca V 1.3 for pacemaking. Conversely, dopaminergic neurons in the ventral tegmental area, which is adjacent to the substantia nigra, that are less affected by neurodegeneration in Parkinson's disease rely instead upon sodium ion entry for maintenance of conductance oscillations. Furthermore, other neurons that use Ca V 1.3 channels that do not degenerate in Parkinson's disease, for example striatal spiny neurons, do not exhibit pacemaking but are instead only episodically activated [24] [25] [26] [27] [28] . The use of calcium rather than sodium ions for pacemaking requires much more energy expenditure to maintain a safe non-toxic intracellular calcium concentration. Furthermore, combined with the structural phenotype of susceptible neurons and differential calcium-binding protein distribution described above, these factors may explain why some neurons degenerate more in affected areas of brain (e.g. ventral-lateral zone [ dorsal tier of the substantia nigra) in Parkinson's disease, whereas other regions containing similar neuron types are less affected (e.g. ventral tegmental area). In Parkinson's disease, where mitochondrial dysfunction is evident, the reliance on Ca V 1.3 channels, should it also occur in humans, together with the other phenotype characteristics mentioned above, may make the substantia nigra pars compacta neurons and other brainstem projection nuclei more susceptible to calcium-mediated excitotoxicity [10, 20, 29] . The reliance on Ca V 1.3 channels for pacemaking in the substantia nigra may also explain the decline in dopaminergic neurons in this region with advancing age [30] , but it does not explain why only some of us get Parkinson's disease. However, Parkinson's disease is not just accelerated ageing; the pattern of cell loss differs in post mortem brains from non-parkinsonian elderly people from that seen in brains from patients dying with Parkinson's disease [31] . As stated above, a number of mechanisms (oxidative stress, mitochondrial impairment, proteasomal dysfunction, excitotoxicity, neuroinflammation, apoptosis) are involved in the neurodegeneration that occurs in Parkinson's disease. However, it should be noted that Ca V 1.3 channels are dispensable in maintaining pacemaking activity because, when dendritic calcium oscillations are eliminated by blockade with dihydropyridines, pacemaking still occurs through a combination of voltage-dependent sodium, potassium and hyperpolarization and cyclic nucleotide-activated cation (HCN) channels, which are all also expressed by autonomously active neurons in the midbrain and brainstem [32] [33] [34] . Consequently, blocking Ca V 1.3 channels should provide a reduction in oxidative stress in surviving neurons (and hence provide neuroprotection) but should not affect their autonomous activity and physiological function (Fig. 1) .
In addition to the unusual electrophysiology of midbrain catecholamine neurons, another separate line of evidence implicates Ca V 1 in the pathogenesis of Parkinson's disease. That is, retrospective analysis of patients treated with Ca V 1 channel-blocking drugs for hypertension and cardiac arrhythmias has found a decreased risk for Parkinson's disease in patients treated with dihydropyridines that cross the blood-brain barrier, which suggested a neuroprotective effect of such drugs and implied a pathogenic role for the Ca V 1 channel subtype in Parkinson's disease [35, 36] . [17, 49, 50, 56, 57] . Early post mortem studies examining the expression of Ca V 1 channels in brains from patients who died with Parkinson's disease used radiolabelled dihydropyridine ligands. Consequently, the studies did not differentiate between isoforms of Ca V 1 channels. Watson et al. [58] found no change in the density of [ 3 H]PN 200-110 (isradipine) binding sites in striatum from patients dying with Parkinson's disease. Likewise, Sen et al. [59] found that the B max (total number of binding sites) and K d (affinity) for [ 3 H]PN 200-110-binding sites was not significantly altered in the striatum, thalamus, temporal cortex or occipital cortex of the parkinsonian brain. Both studies also examined striatal tissue from patients dying from Huntington's disease and measured a significant reduction in Ca V 1 channel-binding sites in this region. These data indicate that Ca V 1 channels were predominantly located on neurons intrinsic to the striatum, since striatal medium-sized spiny neurons degenerate in Huntington's disease [60] . However, an earlier study by Nishino et al. [61] using [ 3 H]nitrendipine reported a decrease in dihydropyridine-binding sites in striatum and substantia nigra from patients dying with Parkinson's disease, which suggested that Ca V 1 channels were present on neurons projecting to the striatum from the substantia nigra. The reason for the differing results is unknown but probably reflects differences in the binding characteristics of the radioligands used to label the Ca V 1 channel isoforms in the brain. Since Nishino et al. [61] measured no change in the prefrontal cortex or globus pallidus, it seems unlikely that the post-mortem delay or agonal state of the patients with Parkinson's disease prior to death caused the reduction in [ 3 H]nitrendipine-binding sites [17] .
Expression of Ca V 1 subtypes was more recently examined in post-mortem human brains by immunohistochemistry and in situ hybridization in areas vulnerable and resistant to neurodegeneration in Parkinson's disease. The expression of Ca V 1.3 was found to be elevated compared with age-matched controls throughout the brain, such that the ratio of Ca V 1 subtypes (Ca V 1.2:Ca V 1.3) differed throughout the brain in patients with Parkinson's disease compared with control subjects in favour of an increased use of Ca V 1.3. Increased use of Ca V 1.3 would add to the metabolic burden for cells that rely on this Ca V 1 subtype for electrical activity and could therefore render specific neuronal populations more vulnerable to neurodegeneration [42, 43] . Furthermore, the increased expression of Ca V 1.3 in the cerebral cortex of early-stage Parkinson's Fig. 1 Numerous molecular mechanisms contribute to the neurodegenerative process in Parkinson's disease and their damage is additive. Preventing excessive calcium influx by blockade of Ca V 1.3 channels with dihydropyridine drugs (e.g. isradipine) would decrease metabolic stress that is caused by expending energy to keep calcium concentrations at nontoxic levels. Treatment with dihydropyridine drugs may therefore result in neuroprotection. The pacemaking function of surviving neurons would not be affected because other ion channels are also able to perform this function [35, 36, 62, 63] , whereas others found no significant effect [64] [65] [66] [67] . However, the consensus-based upon systematic review of all available literature-is that calcium channel blockers do appear to reduce the risk of Parkinson's disease [68, 69] , although the mechanism by which they do so is not completely understood. Ca V 1 subtypes not only regulate neuronal electrical activity and modulate the gating of other ion channels, they also control numerous cellular processes such as neurotransmitter release, neuronal survival, kinase activation, neurite outgrowth and gene transcription. They do this by either influx of calcium into cells following membrane depolarization or release from intracellular stores and are found on non-neuronal cells in brain that are not electrically active [17, 70, 71] . As such, although contentious, it is worth considering additional (or alternative) mechanisms for the prevention of calcium influx into spontaneously active cells, whereby Ca V 1 blockade could lead to neuroprotection. Is the neuroprotection observed in animal models of Parkinson's disease following treatment with isradipine achieved purely through a reduction in mitochondrial oxidant stress [25] ? Or is there also an anti-inflammatory component mediated through modulation of glial cell activity [72] [73] [74] and hence neuroinflammation, through actions on Ca V 1 subtypes present on non-neuronal cells? Furthermore, in addition to a direct effect on neuroinflammation through inhibition of glial cell activity via blockade of Ca V 1 subtypes, reducing blood pressure per se may also be neuroprotective, particularly in Parkinson's disease with co-existing vascular pathology. Hypertension may lead to oxidative stress and inflammation in the brain through actions on the central renin-angiotensin system [75] . An association between hypertension and Parkinson's disease risk was described in women [76] , so there could be an additional indirect mechanism by which calcium channel blockers are neuroprotective other than by directly decreasing intracellular calcium. More selective Ca V 1.3-blocking ligands have recently been described, which should provide a more potent means of reducing mitochondrial oxidant stress in rhythmically firing catecholamine neurons of the midbrain and brain stem [77] . Studies using such ligands in animal models of Parkinson's disease and ultimately in human trials should resolve this issue.
Calcium Channel Blocker Clinical Trials
Preclinical studies in rodent and non-human primate models of Parkinson's disease demonstrated that pretreatment with isradipine (which has an almost equimolar affinity for Ca V 1.2 and Ca V 1.3) or nimodipine could protect dopamine neurons from MPTP-and 6-OHDA-induced toxicity. It was concluded that this occurred through action on nigral Ca V 1.3 channels that resulted in less calcium entering the cells, with a consequent reduction in the energy used and the oxidant stress required to control intracellular calcium levels [25, [78] [79] [80] . Since isradipine was already approved by the US FDA for use in hypertension, a phase II safety and tolerability trial was rapidly organized to determine the safest and highest dose that could be used in patients with Parkinson's disease [81] . The study found that isradipine tolerability was dose dependent and that dizziness and peripheral oedema were the most common side effects. However, no significant symptomatic benefit versus placebo was observed. However, study participants were in the early stages of Parkinson's disease and did not require dopaminergic medication, so the measured effect did not exclude the possibility of clinical benefit if isradipine was given as a long-term adjunct to traditional (dopaminergic) therapies in patients with more advanced disease [81] . As such, a randomised multicentre double-blind placebo-controlled phase III clinical efficacy trial (STEADY-PD III; ClinicalTrials.gov identifier NCT02168842) to test the ability of isradipine to slow Parkinson's disease progression is currently underway, with results expected in early 2019.
Conclusions
We have provided an overview of why disturbed calcium homeostasis could have a role in the pathogenesis of Parkinson's disease and how blockade of the Ca V 1.3 subtype could be a means of mitigating neurodegeneration. The variable disease phenotype could confound the outcome of the isradipine clinical trial, particularly since the trial recruited early cases and these patients might turn out to have an atypical or familial form of the disorder. This means that even if the trial fails, which is so often the case for putative Parkinson's disease treatments that work well in pre-clinical models, the pursuit of calcium channel antagonists should not be abandoned.
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